How much funding has Trisk Bio raised?

Trisk Bio has raised $16.6M in total funding, most recently a Seed round.

Who are Trisk Bio's investors?

Trisk Bio's investors include Matrix Partners, Quiet Capital.

Where is Trisk Bio headquartered?

Trisk Bio is headquartered in London.

Trisk Bio

Custom AAV Manufacturing

London · Founded 2020 · $16.6M raised

Biotech

Headquarters: London
Employees: 1–10
Founded: 2020
Business Model: B2B

Website: triskbio.com
Total Funding: $16.6M
Last Round: $2.0M SeedDec 2021
Rounds: 2

About

Trisk Bio is a London-based contract manufacturer specializing in custom AAV (adeno-associated virus) production for gene therapy developers, offering fully scalable preclinical manufacturing processes from 1e13 vg research-grade batches up to 5e13–1e15 vg for non-human-primate-grade studies. The company develops bespoke, forecastable production processes across all capsid serotypes and transgenes, including high-throughput process optimization and analytical development, to make preclinical AAV manufacturing faster and more affordable. Trisk Bio has partnered with organizations including Dyno Therapeutics and NanoMosaic to expand its capsid engineering and AAV analytics capabilities.

Summary

Trisk Bio is a Biotech company based in London, founded in 2020. It has raised $16.6M in total across 2 rounds, most recently a $2.0M Seed round in Dec 2021. Investors include Matrix Partners and Quiet Capital.